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Abstract 
Aim 
People with psychotic disorders have increased premature mortality in comparison with the 
general population, with high rates of cigarette use a contributing factor. We aimed to 
describe the prevalence of cigarette use and nicotine dependence (ND) in first episode 
psychosis (FEP), and established psychosis; and to investigate associations between clinical 
symptoms and ND. 
Methodology 
Smoking and clinical data were collected from two cohorts: 181 people with FEP recruited as 
part of the Physical Health and Substance Use Measures in First Onset Psychosis (PUMP) 
study and from 432 people with established psychosis recruited as part of the Improving 
physical health and reducing substance use in psychosis randomised controlled trial 
(IMPaCT RCT). 
Results 
The prevalence of cigarette smoking was 78% in FEP and 62% in established psychosis. 
Forty nine percent (n=60) of smokers in the FEP cohort and 69% (n=183) of smokers with 
established psychosis were highly nicotine dependent. Being a highly nicotine dependent 
smoker was significantly associated with higher PANSS positive symptom scores (F= 5.480 
p= 0.004), and with decreased scores on the Rosenberg self-esteem scale (F=3.261, 
p=0.039) in established psychosis. There was no diagnostic specificity identified in relation 
to smoking or ND in both groups. 
Conclusion 
High rates of cigarette usage and nicotine dependence are problems from the early stages 
of psychosis. ND is higher in people with established psychosis. Smoking cessation 
strategies as part of comprehensive management of psychotic disorders at every stage 
require further development and evaluation.  
 
Keywords: schizophrenia; psychotic; smoking; substance use; addiction; physical health 
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1.0 Introduction 
1.1 Smoking carries an increased physical health burden in people with mental illnesses, 
and people with a diagnosis of a mental disorder account for an estimated 40% of all 
cigarette consumption(Substance Abuse and Mental Health Services Administration 2013, 
Meltzer H et al., 1996, Office for National Statistics 2017). People with a diagnosis of 
schizophrenia have smoking rates 6-fold higher than the general population (de Leon and 
Diaz 2005). The most consistent estimate of smoking prevalence in schizophrenia in the UK 
is a rate of 60-65%(Smith et al., 2007, Krishnadas et al., 2012, Kelly and McCreadie 1999, 
Gardner-Sood et al., 2015), a figure reflected in international studies (Dickerson et al., 
2013b, Margolese et al., 2004, Morgan et al., 2013, de Leon et al., 1995, Dickerson et al., 
2018b). This is despite the significant reduction of smoking observed in the general 
population over the past 30 years (39% in 1980 and 17% in 2015)(Office for National 
Statistics 2017). Those with psychotic disorders also smoke more heavily compared to the 
general population (Lohr and Flynn 1992, Kelly and McCreadie 1999, Ziedonis and George 
1997, Hughes et al., 1986).  While 11% of smokers in the general population are heavy 
smokers, 60% (Kelly and McCreadie 1999) -80%(Hughes 1986) of those with schizophrenia 
and other psychotic disorders smoke 25 or more cigarettes daily.   
1.2 Nicotine dependence (ND) in schizophrenia 
Nicotine dependence (ND) has been less frequently measured in people with psychotic 
disorders. ND reflects not only the frequency and quantity of smoking, but features such as 
tolerance and withdrawal, such as the time to first cigarette use per day(Heatherton et al., 
1991). It is associated with increased difficulty in smoking cessation. Prevalence rates for 
high ND in schizophrenia of 32% (Aguilar et al., 2005) to 38% in a UK study (Krishnadas 
2012) have been reported, with overall rates of ND ranging from 38% (Yee et al., 2015) to 
76% (Patkar et al., 2002). The high prevalence of cigarette use and ND in those with 
psychotic disorders renders them especially vulnerable to adverse physical health 
consequences (Morris et al., 2006, McClave et al., 2010, de Leon and Diaz 2005, Dickerson 
2013b). 
1.3 Smoking and clinical symptoms 
Conflicting associations have been described between cigarette smoking and psychotic 
symptoms in schizophrenia. Cross sectional studies in established psychosis have reported 
associations between tobacco use and reduced negative (Zhang et al., 2012, Zhang et al., 
2007, Smith et al., 2001), and positive symptoms(Zhang 2007). However, findings are 
inconsistent, with some studies finding no association between smoking status and clinical 
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symptoms (Barnes et al., 2006, Kelly and McCreadie 1999, Herran et al., 2000, Kotov et al., 
2010), and others linking current smoking with a greater severity of positive(Goff et al., 1992, 
Corvin et al., 2001, Zhang et al., 2013) and negative symptoms(Goff 1992, Cooper et al., 
2012, Iasevoli et al., 2013, Tidey and Williams 2007) and worse cognitive function and 
functional outcomes(Depp et al., 2015). 
The majority of studies relate to established psychosis, with just three studies examining 
links between clinical symptoms and smoking in first episode psychosis (FEP) (Grossman et 
al., 2017, Zhang 2013, Misiak et al., 2015). In a cross sectional study of 109 FEP patients, 
cigarette smoking was associated with fewer depressive and negative symptoms (Misiak 
2015), while in a Chinese study of 244 first episode schizophrenia (FES) smoking was 
associated with increased total and positive psychotic symptoms(Zhang 2013). A more 
recent cross sectional study of 140 FEP patients found no relationship between cigarette 
smoking and psychotic or depressive symptoms (Grossman 2017). 
1.4 Nicotine dependence and clinical symptoms in established psychosis and FEP 
Fewer studies have assessed the association between nicotine dependence and psychotic 
symptom severity in people with psychosis. Some cross sectional studies identified positive 
associations between ND and total and positive psychotic symptoms, (Krishnadas 2012, 
Aguilar 2005), with others reporting associations with decreased negative but not positive 
symptoms (Yee 2015, Patkar 2002, Douglas M. Ziedonis et al., 1994).  Nicotine dependence 
was associated with worse scores on the Clinical Global Impression scale(Herran 2000) and 
worse functional outcomes(Depp 2015). The single study in FEP found reduced depressive 
and negative symptoms in those with severe ND compared to non-smokers (Misiak 2015). 
The paucity of available research and the equivocal study findings preclude definitive 
interpretations of the relationship between cigarette smoking, nicotine dependence and 
clinical symptoms in psychosis. 
1.5 Study aims: 
To assess the role of smoking in psychotic disorders we aimed to:  
 
A) Describe the characteristics and prevalence of cigarette use in FEP and established 
psychosis cohorts.   
B) Determine the rates of nicotine dependence in both cohorts, and examine for 
associations between nicotine dependence and demographic and clinical 
characteristics.  
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2. Material and Methods 
2.1 Cohorts and settings 
First episode psychosis (FEP) cohort 
Baseline data from 181 FEP patients recruited in both inpatient and outpatient settings in 
three UK Mental Health Trusts as part of the Physical Health and Substance Use Measures 
in First Onset Psychosis (PUMP) study, part of the NIHR-funded, Improving Health and 
Reducing Substance Use in Psychosis (IMPaCT) programme ((Lally et al., 2018a, Lally et 
al., 2017) Gaughran et al, submitted). 
Established psychosis cohort 
Baseline data from 432 patients with established (multi-episode) psychosis recruited from 
community mental health teams (CMHTs) in five Mental Health NHS Trusts as part of the 
NIHR funded IMPaCT randomised controlled trial (RCT) (Improving physical health and 
reducing substance use in severe mental illness) (Gaughran et al., 2013, Gaughran et al., 
2017).  
2.2 Subjects 
FEP cohort 
Participants were aged 18-65 years and were proficient in English with no requirement for an 
interpreter. Patients were eligible if they met the ICD-10 criteria for psychosis (ICD-10 codes 
F20-29 and F30-33) diagnosed utilising the OPCRIT (McGuffin et al., 1991) and had made 
first contact with health services for psychotic symptoms not more than 12 months 
previously. Patients were consented as soon after first presentation with psychosis as 
possible."Exclusion criteria included comorbid major medical illness or neurological disease; 
diagnosed severe learning disability; an organic cause for their psychosis; or history of 
previous contact with health (GP or Psychiatric) services for the presence of psychosis. 
 
 
Established psychosis cohort   
The inclusion criteria were as follows: capacity to provide written informed consent to 
participate (Lally et al., 2018b); aged between 18-65 years old; a primary diagnosis of a 
psychotic illness (ICD-10 diagnosis: F20-29, including schizophrenia, schizoaffective 
disorder, bipolar affective disorder and delusional disorder, F31.2, F32.3 and F33.3), 
Exclusion criteria included a primary diagnosis of intellectual disability (as defined by ICD-10 
codes F70-F79 for intellectual disabilities); a first episode of psychosis (FEP); a primary 
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substance misuse disorder (excluding tobacco); a serious physical illness that could 
independently impact metabolic measures; pregnant or up to six months postpartum; and 
receiving intensive input for a medical or terminal condition.  
 
2.3 Clinical and sociodemographic variables 
Sociodemographic and clinical data were collected including gender, age, ethnicity, 
education, relationship status and living circumstances and diagnosis along with self-
reported duration of illness (established psychosis cohort only).  
Participants’ mental health status was measured using the Positive And Negative Syndrome 
Scale (PANSS) (Kay et al., 1989); depression was assessed using the Montgomery Asberg 
Depression Rating Scale (MADRS) (Montgomery 1979) in the established psychosis cohort 
and Calgary Depression Rating Scale (CDRS) (Addington et al., 1990) in those with FEP. 
Alcohol use was measured using the Alcohol Use Disorders Identification Test (AUDIT) 
(Saunders 1993). In addition, the Rosenberg Self Esteem scale was applied in the 
established psychosis cohort (Rosenberg 1965). 
2.4 Tobacco Smoking  
Current smoking use was recorded using the Fagerström Tolerance Questionnaire (FTQ)  
(Fagerstrom and Schneider 1989, Fagerstrom 1978, Heatherton 1991). The FTQ measures 
nicotine dependence. It is an 6 item scale which produces a range of scores from 0-11.  
Data for all measures were collected through face-to-face interviews conducted by trained 
research assistants. Total scores on the FTQ were derived from individual scale items.  
Smoking status was assessed at baseline using the question ‘do you currently smoke (at 
least one per week)?’ All participants who smoked were administered the FTQ to measure 
nicotine dependence. ND has been classified as very high nicotine dependence (score of 
>7), medium to high nicotine dependence (score of 5-7), mild nicotine dependence (score 2-
4) and low or absent dependence (score 1-2)(Horn et al., 2003, Kimberly et al., 1999).  
Based on the exploratory nature of our study, and the sample size, dichotomized FTQ 
scores were used. For this study we categorized the FTQ scores into two categories, high 
and low dependence based on a median split in the FTQ total score(Morris et al., 2016). On 
the basis of the FTQ scores, smokers in both the FEP and the established psychosis cohorts 
were classified as displaying high dependence (FTQ ≥5 (equivalent to moderate to very high 
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dependence); or low dependence (FTQ ≤ 4 (equivalent to mild to low dependence)); non-
smokers were the third category.  
We recorded the total number of all types of cigarettes and other forms of tobacco-smoked 
daily. We classified those who smoked ≥20 cigarettes or other tobacco products to be heavy 
smokers, as used in other studies(Kay-Lambkin et al., 2013, Alati et al., 2004, Grossman 
2017).  
2.5 Statistical analysis  
Statistical analyses were performed using the IBM Statistical Package for Social Sciences 
Statistics for Windows, Version 22.0 (Armonk, NY: IBM Corp). Descriptive measures were 
used for the basic demographic and clinical variables as well as for variables relating to the 
evaluation of smoking frequency and severity of nicotine dependence. Cross-comparisons 
were performed to calculate smoking prevalence by gender, ethnicity, diagnostic group and 
nicotine dependence status. The student-t test for parametric data and the Chi square (x2) 
test for categorical variables were employed. Comparisons between groups for continuous 
variables were conducted using independent t-tests and Analysis of Variance (ANOVA). 
Demographic and clinical variables for high dependence smokers, mild dependence 
smokers and non-smokers were compared using an ANOVA. Post hoc analyses using the 
Tukey HSD post hoc criterion for significance were conducted where ANOVA demonstrated 
significant differences between the group means. All statistical tests were two-sided and a p 
value ≤ 0.05 was considered statistically significant. 
 
3. Results 
3.1 The demographic and clinical characteristics of those in the total FEP and established 
psychosis study populations are shown in supplementary tables 1 and 2.  
Seventy eight percent of those with FEP and 62% of those with established psychosis were 
current smokers (Table 1). Those with FEP smoked a mean of 10.7 (SD=6.6) (median=10.0) 
cigarettes per day, while in those with established psychosis the mean number of cigarettes 
smoked per day was 16.4 (SD=8.5) (median=16.0).  Eighteen percent (n=43) of those with 
established psychosis smoked more than 20 cigarettes per day, compared to 3% (n=2) of 
those with FEP.  
The mean FTQ score in those with established psychosis was 5.2 (SD=1.6) (median=5.0) 
and 4.5 (1.9) (median=5.0) in those with FEP. The rate of high ND was 69% in established 
psychosis, and 49% in FEP.  
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3.2 First episode psychosis   
There were 141 current smokers (81% of males (n=100) and 71% of females (n=41). 
Females smoked on average 12.0 (SD=8.3) cigarettes per day and males 10.3 (SD=5.8) 
(t=1.023, p=0.310).  
A higher proportion of people with a diagnosis of a non-schizophrenia FEP (85%; n=51) 
smoked compared to those with a diagnosis of first episode schizophrenia (71%; n=50) 
(x=3.433, p=0.049). Only two cases (both female) were heavy smokers, smoking more than 
20 cigarettes per day. 
The criteria for ND were met by 74% (n=120), with 49% (n=60) having high dependence with 
no gender differences noted . There were no significant differences between those of 
different ethnicities in severity of ND or number of cigarettes smoked per day. Nor were any 
significant differences detected in diagnostic subgroups, psychotic symptoms or depressive 
symptoms between ND categories and non-smokers (Table 2). 
Those with high ND had significantly higher mean AUDIT scale scores (mean 13.6 
(SD=11.0), compared to those with low dependence (mean=9.2 (SD=7.2) and non-smokers 
(mean=7.7 (SD=7.8) (F=5.968, p=0.03).  
3.4 Established psychosis 
Among 432 patients, 268 (62%) were current smokers and 61% (n=264) met criteria for ND. 
Of those, 83 (31%) met criteria for low nicotine dependence, and 183 (69%) for high nicotine 
dependence.  
Males (73%, n=178) were more likely than females (48%, n=90) to smoke (x2=27.085, 
p<0.001) (supplementary table 2), although the average number of cigarettes smoked daily 
was similar in males  (16.3 (SD=8.6)) and females (16.8 (SD=8.4) (t=0.431, p=0.667).  
A similar proportion of male (16.1%; n=26) and female smokers (20.5%, n=17) were heavy 
smokers (x2=0.708, p=0.251). Those of white ethnicity were more likely to be heavy smokers 
(23.3%; n=31) than those of other ethnic groups (x2=8.092, p=0.044). A trend was evident 
towards a smaller proportion of people with a diagnosis of schizophrenia being heavy 
smokers (14.0%; n=24) compared to those with a diagnosis of affective psychosis (24.6%; 
n=16) (t=3.474, p=0.053). 
Increased rates of high ND were observed in males (52%; n=127) compared to females 
(30%; n=56) (x=27.5; p<0.001); in those of white ethnicity (49%; n=108) compared to those 
of black ethnicity (37%; n=50), Asian ethnicity (20%; n=3), and those of mixed or other 
ethnicity (31%; n=9) (x=17.068, p=0.009); and in people living in supervised accommodation 
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(52.7%; n=49) compared to those living in other settings (F=30.036, p<0.001) 
(supplementary table 2).  
On tests of between-participants effects, dependence status was significantly associated 
with PANSS positive symptom scores (F= 5.480 p= 0.004) and trended towards a significant 
association with total PANSS scores (F=2.914, p=0.055), but not PANSS negative 
symptoms scores (F = 0.397; P = 0.672)(Table 3).  
Those with high ND had greater rates of depression (defined by MADRS score > 6) (46%; 
n=121) compared to those with low ND (16%; n=42) and non-smokers (38%; n=98) 
(x=6.397; p=0.041), although there was no difference on continuous MADRS measures.  
Those with high ND had lower scores on the Rosenberg self-esteem scale (mean=17.1 
(SD=5.6), compared to those with low dependence (mean=19.0 (SD=6.6)) (F=3.261, 
p=0.039). Those with high ND had lower scores than non-smokers (mean=18.3 (SD=5.3), 
but this did not meet statistical significance (p=0.171).  
Patients with high nicotine dependence had higher mean AUDIT scores (mean 7.2 (SD=6.1), 
compared to those with low dependence (mean=6.2 (SD=5.2) and non-smokers (mean=3.4 
(SD=3.6) (F=12.616, p<0.001).   
4.0 Discussion  
Smoking rates are high in both FEP (78%) and established psychosis (62%) despite the 
reductions in cigarette use in the general population. Our 78% figure in FEP population is 
higher than previous FEP studies that identified rates of 36-53% (Misiak 2015, Zhang 2013, 
Grossman 2017)and over 3 times higher than rates in the UK general population for a 
comparable age range (16-34 years)(Office for National Statistics 2017). Similar rates of 
cigarette use (78%) were identified in an Australian cohort of 126 FEP patients(Wade et al., 
2005).  
High levels of ND were seen in both FEP and established psychosis, but high ND was more 
prevalent in established psychosis. This suggests that cigarette use is established early in 
the course of psychotic illness, if not before (Gurillo et al., 2015), while dependence 
increases over time. An association between duration of illness and ND status has not been 
previously identified (Krishnadas 2012). However, it remains possible that difference in ND 
levels between stages of illness may be explained by secular trends. The variance in degree 
of ND may relate to longitudinal changes in social and legal policy in relation to cigarette use 
such as smoking being prohibited in public places, and higher costs, potentially making it 
easier to refrain from smoking in public places and the cost of cigarettes limiting the number 
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smoked in the younger FEP cohort. 
4.1 Nicotine dependence in Established psychosis 
Age, relationship status, level of education and duration of illness did not differ between 
smokers and non-smokers, or with degree of ND. In those with established psychosis, males 
were more likely to smoke and have greater nicotine dependence than females, in keeping 
with previous work(de Leon and Diaz 2005, Dixon et al., 2007), although this was not evident 
in those with FEP. People with established psychosis of white ethnicity were more nicotine 
dependent and more likely to smoke more than 20 cigarettes per day in comparison to those 
from other ethnic groups, in keeping with previous work (Dixon 2007) and mirroring  general 
population studies(Trinidad et al., 2009, Caraballo et al., 1998, Hahn et al., 1990).  
The higher rate of ND in those living in supported accommodation was notable and may 
offer opportunity for intervention. People who need supervised accommodation often have 
functional impairment secondary to their psychotic disorder and the greater ND in this 
population may make smoking cessation more challenging.  
4.2 Diagnostic subgroups and tobacco smoking 
We found no relationship between ND and diagnosis. Prior studies have found a lack of 
diagnostic specificity with smoking status in both FEP(Grossman 2017), (Kotov 2010) and 
established psychosis(Corvin 2001), but have not examined ND.  
We noted higher rates of smoking in non-schizophrenia FEP compared to first episode 
schizophrenia (FES). Only two cases (1%) in the FEP group were heavy smokers, much 
less than 19% (27/140) identified in a recent cross sectional analysis of smoking in FEP 
(Grossman 2017).   
The mean number of cigarettes smoked per day in the established psychosis group of 16.4, 
is higher than the general population average of 11 cigarettes per day(Office for National 
Statistics 2013), although there was no impact of diagnosis of schizophrenia versus non-
schizophrenia psychotic disorders.   
4.3 Clinical correlates 
In established psychosis, being a highly nicotine dependent smoker was associated with 
increased positive symptoms. This replicates two prior studies, which identified a similar 
relationship in schizophrenia (Krishnadas 2012, Aguilar 2005), and expands on these 
findings with the inclusion of schizophrenia and other psychotic disorders. A recent 
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prospective cohort study identified associations between smoking and increased positive, 
negative and depressive symptoms in 1094 people with non affective psychosis who 
smoked, indicating that smoking is associated with worsening of clinical state(Vermeulen et 
al., 2019). 
For the first time, we identified a significant relationship between high ND and lower self-
esteem in people with established psychosis. This is a novel finding and one, which may 
point towards strategies to address low self-esteem in aiding smoking reduction and 
cessation in this population. In the general population, most evidence exists in adolescent 
and young adult populations to support associations between improved self-esteem and 
lower smoking rates(Carvajal et al., 2000). This relationship seems to be more evident in 
males, with increased smoking behaviour and pro-smoking beliefs relating to low self 
esteem(Hale et al., 2015). 
To the best of our knowledge this is the second study to investigate associations between 
ND and clinical symptoms in early psychosis. In contrast to the previous study in FES which 
identified an association between lower negative and depressive symptoms in those with 
severe ND compared to non-smokers(Misiak 2015), we found no significant associations 
between clinical symptoms and ND compared to non-smokers. 
Other studies in FES identified associations between smoking and positive symptoms 
(Zhang 2013), though similar to Grossman et al, we did not identify associations between 
smoking and clinical symptoms in our FEP group(Grossman 2017).  
 
As expected, smokers with high ND in both populations had higher rates of hazardous 
drinking than non-smokers. Previous epidemiological studies have indicated increased rates 
of alcohol use disorders in smokers with established psychosis (Degenhardt and Hall 2001, 
Hartz et al., 2014).  
 
4.4 Strengths and Limitations 
The cross-sectional nature of this study limits interpretation regarding casual inference 
regarding the relationship between ND, and cigarette smoking and clinical symptoms.  
However, our established psychosis population were a reasonably stable cohort living in the 
community with average illness duration of 15 years.  The use of multiple statistical tests 
may have increased the risk of type I errors, and our findings require replication in 
longitudinal cohorts. 
16"
"
The use of cigarettes was self-reported, thus raising the possibility of reporting bias in that 
patients may have inaccurately reported consumption. However, we also recorded ND as 
measured by the FTQ, with the measure of ND not wholly reliant on establishing heavy 
smoking, the frequency of cigarette use, or duration of smoking (which might be affected by 
self-report measures of cigarette use). The use of a validated scale to measure ND provides 
a reliable measure of smoking use in this population.  Further, our findings in relation to ND 
rates are largely consistent with prior work in psychotic disorders. We did not include data on 
antipsychotic medication or use of illicit substances, which may potentially have influenced 
outcomes. Specifically in our established psychosis cohort, some of whom were treated with 
clozapine, smoking may have been associated with induction of antipsychotic metabolism, 
leading to reductions in plasma antipsychotic concentrations, and potentially impairing 
antipsychotic effectiveness(Lally et al., 2016). Though in those with maintenance medication 
regimens, antipsychotic dosing may have been adjusted to account for this to maintain 
clinical stability. However, this remains speculative, as medication use and doses are not 
measured in this study  
 
4.5 Need for smoking cessation implementation  
Despite these limitations, our study indicates that smoking is highly prevalent across the 
lifespan of psychotic illness, and increased focus on smoking cessation in these populations 
is required given the reduced life expectancy and burden of (Azad et al., 2016) disease in 
these populations(Correll et al., 2017, Hjorthøj et al., 2017). Cigarette smoking in psychotic 
disorders further exacerbates the risk of cardiovascular disease, respiratory disease and 
premature mortality(Bobes et al., 2010, Correll 2017, Kelly et al., 2011), doubling the risk of 
natural cause mortality(Dickerson et al., 2018a). An 11 year follow up of 517 people with 
schizophrenia showed an overall Standardised Mortality Ratio of 2.80, with smoking found to 
be strong predictor of death with a relative risk of 4.66 (Dickerson et al., 2013a). Further, a 
prospective study showed that smoking was associated with increased psychotic symptoms, 
refuting that this is due to reverse causation by mechanisms such as self-medication to 
improve psychotic symptoms(Vermeulen 2019). The potential for smoking as a risk factor for 
the development of schizophrenia has been shown, with those who smoke more than 10 
cigarettes a day at the age of 16, having a three fold increased risk of developing a 
psychotic disorder by the age of 30(Mustonen et al., 2018), adding to findings from meta 
analysis indicating that cigarette smoking is associated with the earlier onset and increased 
risk of psychotic illness (Gurillo 2015).  Until recently, clinicians have been unduly 
pessimistic about the prospect of reducing smoking rates in psychosis. However, study 
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findings have demonstrated that people with schizophrenia want to stop smoking and that it 
is possible to help them to do so (Banham and Gilbody 2010, Hall and Prochaska 2009, 
Ziedonis et al., 2008, Gandhi et al., 2019). Abstaining from cigarette use in schizophrenia 
does not worsen mental state(Evins et al., 2007), and the use of smoking cessation agents 
such as bupropion and varenicline can be successfully used without worsening 
psychosis(Tsoi et al., 2013). 
It appears that levels of ND are broadly consistent across diagnostic groups, as are factors 
contributing to increased smoking and higher levels of ND. Potentially important contributing 
factors (and avenues for therapeutic intervention) in established psychosis include being 
housed in supervised accommodation, and lower self-esteem in smokers with higher ND.  
6. Conclusion 
We found a significant association between ND and positive symptoms of psychosis in 
established psychosis, though no such relationship was identified in FEP. Our study builds 
on prior research in established psychosis to indicate that smoking and ND remain 
significant health risks in this population. Larger prospective studies, to explore relationships 
between smoking, ND and clinical symptoms are required. The 3-fold greater smoking rates 
than the general population highlights the need for a reinvigorated approach to smoking. 
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Table 1 Smoking characteristics of FEP and established psychosis study populations 
 
 FEP (n=181) Established Psychosis 
(n=432) 
Smoking status, n (%) 
Current smoker 
Non-smoker  
Never smoked 
 
141 (77.9%) 
40 (22.1%) 
29 (17.7%) 
 
268 (62.0%) 
164 (38.0%) 
108 (25.0%) 
Number of cigarettes /day, n(%) 10.7 (6.6) 16.4 (8.5) 
Number of cigarettes smoked 
per day, categories 
<11 
11-20 
>20 
 
 
55 (70.5%) 
21 (26.9%) 
2 (2.6%) 
 
 
82 (33.6%) 
119 (48.8%) 
43 (17.6%) 
   
Fagerstrom tolerance 
questionnaire (FTQ) score 
(mean) (SD) 
4.5 (1.9) 
 
5.2 (1.6) 
 
FTQ category of dependence, n 
(%) 
Low/absent 
Mild 
Moderate 
High                           
 
 
3 (2.4%) 
60 (48.8%) 
50 (40.7%) 
10 (8.1%) 
 
 
2 (0.8%) 
81 (30.5%) 
166 (62.4%) 
17 (6.4%) 
 
Table 2 Clinical characteristics in in FEP patients according to their nicotine dependence 
status 
 Total sample 
(n=181) 
Non-smoker  
(n=40) 
Low Nicotine 
dependence  
(n=63) 
High Nicotine 
dependence 
(n=60) 
T/F test; p 
value 
Age  
(mean (SD) 
28.4 (9.7) 29.5 (10.3) 26.3 (7.0) 29.6 (10.6) 1.913; 0.152 
PANSS  
Total 
Positive 
Negative 
 
59.0 (14.9) 
14.8 (6.1) 
14.6 (5.8) 
 
 
56.3 (13.1) 
13.6 (5.8) 
13.0 (4.6) 
 
59.5 (15.2) 
15.8 (6.9) 
15.0 (6.4) 
 
 
60.7 (15.5) 
14.7 (4.9) 
15.6 (6.1) 
 
0.837; 0.436 
1.243; 0.292 
1.836; 0.164 
Calgary 
depression 
scale score 
5.3 (5.2) 4.8 (3.6) 4.6 (4.8) 6.5 (6.2) 1.905; 0.153 
AUDIT scale 
score 
10.5 (9.1) 7.7 (7.8) 9.2 (7.2) 13.6 (11.0)* 5.968; 
p=0.03 
* p<0.05  
Table 3 Clinical characteristics in patients with established psychosis according to their 
nicotine dependence status 
 Total sample 
(432) 
Non-smoker  
(n=164) 
Low Nicotine 
dependence  
(n=83) 
High Nicotine 
dependence 
(n=183) 
F test; p 
value 
Age  
mean (SD) 
44.2 (10.1) 45.8 (10.6) 43.4 (10.2) 43.2 (9.5) 2.988; 0.051 
Duration of 
illness 
15.4 (10.0) 15.0 (9.7) 15.4 (10.8) 15.7 (10.0) 0.143; 0.867 
PANSS  
Total 
Positive 
Negative 
 
51.3 (14.1) 
11.8 (5.0) 
12.9 (4.9) 
 
 
49.4 (13.5) 
10.8 (4.3) 
12.6 (4.8) 
 
51.1 (14.3) 
11.8 (5.1) 
13.1 (4.9) 
 
 
53.0 (14.3) 
12.6 (5.3)** 
13.0 (5.1) 
 
2.914; 0.055 
5.480; 0.004 
0.397; 0.672 
MADRS 11.0 (9.5) 10.2 (8.3) 10.4 (10.6) 12.0 (9.8) 1.807; 0.165 
Rosenberg 
Self Esteem 
Scale Score 
17.9 (5.8) 18.3 (5.30 19.0 (6.6) 17.1 (5.6)* 3.261; 0.039 
AUDIT scale 
score 
5.71 (6.1) 3.4 (3.6) 6.2 (5.2) 7.2 (6.1)*** 12.616; 
p<0.001 
 
* p<0.05; ** p<0.01 ; *** p<0.001 
